- 10:28 AM Financial stability, climate change top on EU Prez...
- 10:27 AM UK joins G20 push for world levy on banks
- 10:27 AM Britain urges divided G20 to reach climate finance...
- 10:27 AM G20 leaders meet, talk about climate change, world...
- 06:47 PM 'The Sensex will test 14,500 at some point…'
- 04:16 PM See scope for more int'l listings of Indian cos: N...
- 04:12 PM Dollar weakness will boost EMs, commodities ahead:...
- 04:07 PM 'India would've grown at 7% had monsoon not played...
- 03:04 PM Bye-bye Circular 23!
- 03:00 PM CavinKare eyes Rs 100cr revenues from restaurant b...



Broking house, P-sec is bullish on Nicholas Piramal and has maintained buy rating with a price target of Rs 268.
P-sec report on Nicholas Piramal:
|
RSS feed for news about this stock Click here |
"Nicholas Piramal reported 31% yoy growth in the topline during Q1 FY07 and 7% yoy growth in the net profit during the same period. Lower growth in the bottomline was mainly because of Avecia loss and poor growth in domestic formulations business on account of Valdecoxib and VAT effects. The company has wide presence in nine therapeutic segments including Respiratory, CVS, CNS, Anti- diabetic, Bio-technology etc which accounts for 90% of the market."
"Pathlabs segment is growing at strong 33% yoy and the company has indicated this growth rate to continue. We expect it to grow at 12-13% over next couple of years as compared to 8-10% market growth rate."
"At CMP of Rs 217, the stock is trading at 19.7x FY07P and 14.5x FY08E earnings and is trading at discount to its peers like Divis’s Labs, Dishman Pharma and inline with Jubilant Organosys. We recommend a buy on the stock with a target price of Rs 268."
|
Stock Advice
|
|
|


Today's Special Column
with Kishore Biyani
Future Group and the MD of Pantaloon Retail (India) Limited , Group CEO


-
Most Read
-
Most Viewed
- 10 Companies that FIIs love
- 10 companies that MF managers love
- 'The Sensex will test 14,500 at some point…'
- Mahindra Satyam restarts hirings, recalls bench
- Exit Suzlon Energy at Rs 83: Joshi

- 'Bullish' Mark Mobius unfazed by recent market correction
- Sensex ends week 262 pts up, sectors to look at ahead

- SBI cuts deposit rates on slow credit, liquidity glut
- 'The Sensex will test 14,500 at some point…'
Source: CNBC-TV18
- See scope for more int'l listings of Indian cos: NYSE
Source: CNBC-TV18
- Dollar weakness will boost EMs, commodities ahead: HSBC
Source: CNBC-TV18
- 'India would've grown at 7% had monsoon not played truant'
Source: CNBC-TV18
- SBI cuts deposit rates on slow credit, liquidity glut
Source: Business Line
- Aurobindo drug gets US nod
Source: Business Line
- BEML bags Rs 185 cr NCL order
Source: Business Line
- Tatas going global with low-cost housing
Source: Business Line





















